-+ 0.00%
-+ 0.00%
-+ 0.00%

Missed Sasol's 187% Run? What Holders Had To Believe

Simply Wall St·10/24/2026 02:38:23
語音播報

Holding Sasol from the start of the year would have returned 186.9%, including dividends. That kind of move makes any investor ask what was really on the table back in January, when bulls were talking up renewable projects and margin recovery while bears warned about climate regulation, high debt, and stranded coal assets. If you had to make that call again using only what was on record then, what would you have focused on most?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

If the move has made Sasol harder to judge, start where the gap is still open and scan 192 high quality undervalued stocks.

The Argument You Would Have Had To Settle On Sasol

The shares cost ZAR106 at the start of the period, and anyone looking at Sasol then had to decide which story felt more convincing.

The bull Narrative put Fair Value at ZAR134, or 26% above the start price. That view leaned on Sasol lifting revenue by 4.0% a year and pushing profit margin to 8.1%, supported by renewable projects and specialty chemicals.

The bear Narrative pointed to a Fair Value of ZAR70, or 34% below the start price. That camp focused on climate regulation, stranded coal assets, and heavy debt as the key threats.

JSE:SOL Trailing 12-Month Earnings & Revenue History as at Oct 2026
JSE:SOL Trailing 12-Month Earnings & Revenue History as at Oct 2026

What The Results Put To The Test For Sasol

Sasol’s H2 2026 report showed revenue of ZAR149,731m and net income of ZAR11,908m, with net margin at 8.0%. That outcome sat close to the bull case margin assumption and challenged the idea that profitability would remain structurally weak. The gas project talks in Mozambique gave the optimistic story another data point, so the period mainly supported the optimistic case.

The useful takeaway is simple. When a thesis hangs on margin repair, track the reported net margin against the original forecast and how many periods it holds. Do not focus only on whether revenue moved.

What Sasol’s Run Up Leaves You Paying For Today

Sasol now trades at ZAR301, well above the level where this cautious Narrative places Fair Value. The argument is that the share price embeds rich expectations while the business is still working through meaningful transition and balance sheet questions.

The Narrative highlights margin support from renewables and specialty chemicals but keeps coming back to coal-heavy assets, debt and softer chemicals demand. A buyer at today’s price is assuming those headwinds do not derail steady profit growth, so the question is how that sits against the highlighted execution and ESG risks.

"Sasol's core reliance on coal-to-liquids and gas-to-liquids technology exposes it to long-term decarbonization pressures, rising carbon tax and regulatory risk, and potential demand erosion for fossil-based products, which could compress net margins and reduce future earnings. Persistent operational challenges, including ongoing coal quality and gasifier availability issues, slow ramp-up of new projects (like the destoning plant), and production volume fluctuations, create risk of failing to restore or grow revenue, limiting deleveraging and hampering profit growth."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

How Could You Get There Earlier?

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

  • Company 1 - 24% below our estimate - powers cloud-based infrastructure that enterprises integrate into existing workflows and codebases.
  • Company 2 - 49% below our estimate - equips data centers upgrading to higher margin electrical power and liquid cooling systems.
  • Company 3 - 23% below our estimate - develops clinically tested probiotic products meeting preventative health demand in retail distribution.

Three companies from the same screener. Open all 204 companies with the balance sheet to back it up →